Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer
Phase 2
N/A
N/A
N/A
N/A
Not Enrolling
Male
Metastatic Prostate Cancer
Male
Metastatic Prostate Cancer
Trial Information
Efficacy of Docetaxel (J 15) and Celecoxib in Metastatic Prostate Cancer
Association Docetaxel (J 15) and celecoxib Patient survival Biological parameter : PSA
Clinical status RECIST evaluation
Inclusion Criteria:
- metastatic prostate cancer
- ASCO progression criteria
Exclusion Criteria:
- other prostate chemotherapy
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Principal Investigator
Christian PFISTER, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Hospital, Rouen
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
2003/052/HP
NCT ID:
NCT00213694
Start Date:
November 2003
Completion Date:
June 2006
Related Keywords:
- Metastatic Prostate Cancer
- Prostatic Neoplasms
Name | Location |
|---|
